Your browser doesn't support javascript.
loading
Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration.
Skorvanek, Matej; Martinez-Martin, Pablo; Kovacs, Norbert; Rodriguez-Violante, Mayela; Corvol, Jean-Christophe; Taba, Pille; Seppi, Klaus; Levin, Oleg; Schrag, Anette; Foltynie, Thomas; Alvarez-Sanchez, Mario; Arakaki, Tomoko; Aschermann, Zsuzsanna; Aviles-Olmos, Iciar; Benchetrit, Eve; Benoit, Charline; Bergareche-Yarza, Alberto; Cervantes-Arriaga, Amin; Chade, Anabel; Cormier, Florence; Datieva, Veronika; Gallagher, David A; Garretto, Nelida; Gdovinova, Zuzana; Gershanik, Oscar; Grofik, Milan; Han, Vladimir; Huang, Jing; Kadastik-Eerme, Liis; Kurtis, Monica M; Mangone, Graziella; Martinez-Castrillo, Juan Carlos; Mendoza-Rodriguez, Amelia; Minar, Michal; Moore, Henry P; Muldmaa, Mari; Mueller, Christoph; Pinter, Bernadette; Poewe, Werner; Rallmann, Karin; Reiter, Eva; Rodriguez-Blazquez, Carmen; Singer, Carlos; Tilley, Barbara C; Valkovic, Peter; Goetz, Christopher G; Stebbins, Glenn T.
Afiliação
  • Skorvanek M; Department of Neurology P. J. Safarik University Kosice Slovak Republic.
  • Martinez-Martin P; Department of Neurology University Hospital L. Pasteur Kosice Slovak Republic.
  • Kovacs N; National Center of Epidemiology and Centro de Investigación Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED) Carlos III Institute of Health Madrid Spain.
  • Rodriguez-Violante M; Department of Neurology University of Pécs Pécs Hungary.
  • Corvol JC; MTA-PTE Clinical Neuroscience MR Research Group Pécs Hungary.
  • Taba P; Movement Disorders Unit Instituto Nacional de Neurologia y Neurocirugia Mexico Distrito Federal Mexico.
  • Seppi K; Département des Maladies du Système Nerveux Sorbonne Universités Université Pierre et Marie Curie (UPMC) Paris 06; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-1127 CIC-1422; CNRS UMR-7225; Assistance Publique-Hôpitaux de Paris (AP-HP); and Institut du Cerveau et de la Moe
  • Levin O; Department of Neurology and Neurosurgery University of Tartu Tartu Estonia.
  • Schrag A; Department of Neurology Medical University of Innsbruck Innsbruck Austria.
  • Foltynie T; Department of Neurology Russian Medical Academy of Postgraduate Education Moscow Russia.
  • Alvarez-Sanchez M; Department of Clinical Neuroscience University College London Institute of Neurology London UK.
  • Arakaki T; Sobell Department of Motor Neuroscience University College London Institute of Neurology London UK.
  • Aschermann Z; Department of Movement Disorders and Neurodegeneration Centro Internacional de Restauración Neurológica (CIREN) La Habana Cuba.
  • Aviles-Olmos I; Department of Neurology Hospital Ramos Mejia Buenos Aires Argentina.
  • Benchetrit E; Department of Neurology University of Pécs Pécs Hungary.
  • Benoit C; Sobell Department of Motor Neuroscience University College London Institute of Neurology London UK.
  • Bergareche-Yarza A; Département des Maladies du Système Nerveux Sorbonne Universités Université Pierre et Marie Curie (UPMC) Paris 06; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-1127 CIC-1422; CNRS UMR-7225; Assistance Publique-Hôpitaux de Paris (AP-HP); and Institut du Cerveau et de la Moe
  • Cervantes-Arriaga A; Département des Maladies du Système Nerveux Sorbonne Universités Université Pierre et Marie Curie (UPMC) Paris 06; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-1127 CIC-1422; CNRS UMR-7225; Assistance Publique-Hôpitaux de Paris (AP-HP); and Institut du Cerveau et de la Moe
  • Chade A; Department of Neurology Donostia Hospital Biodonostia Institute and Centro de Investigación Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED) San Sebastian Spain.
  • Cormier F; Clinical Neurodegenerative Diseases Research Unit Instituto Nacional de Neurología y Neurocirugía Mexico City Mexico.
  • Datieva V; Movement Disorders Unit Institute of Neurosciences Favaloro University Institute of Cognitive Neurology Buenos Aires Argentina.
  • Gallagher DA; Département des Maladies du Système Nerveux Sorbonne Universités Université Pierre et Marie Curie (UPMC) Paris 06; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-1127 CIC-1422; CNRS UMR-7225; Assistance Publique-Hôpitaux de Paris (AP-HP); and Institut du Cerveau et de la Moe
  • Garretto N; Department of Neurology Russian Medical Academy of Postgraduate Education Moscow Russia.
  • Gdovinova Z; Barts Health National Health Service Trust The Royal London Hospital London UK.
  • Gershanik O; Department of Neurology Hospital Ramos Mejia Buenos Aires Argentina.
  • Grofik M; Department of Neurology P. J. Safarik University Kosice Slovak Republic.
  • Han V; Department of Neurology University Hospital L. Pasteur Kosice Slovak Republic.
  • Huang J; Movement Disorders Unit Institute of Neurosciences Favaloro University Institute of Cognitive Neurology Buenos Aires Argentina.
  • Kadastik-Eerme L; Department of Neurology Comenius University Martin Slovak Republic.
  • Kurtis MM; Department of Neurology P. J. Safarik University Kosice Slovak Republic.
  • Mangone G; Department of Neurology University Hospital L. Pasteur Kosice Slovak Republic.
  • Martinez-Castrillo JC; Division of Biostatistics University of Texas School of Public Health at Houston Houston Texas USA.
  • Mendoza-Rodriguez A; Department of Neurology and Neurosurgery University of Tartu Tartu Estonia.
  • Minar M; Movement Disorders Program Department of Neurology Hospital Ruber Internacional Madrid Spain.
  • Moore HP; Département des Maladies du Système Nerveux Sorbonne Universités Université Pierre et Marie Curie (UPMC) Paris 06; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-1127 CIC-1422; CNRS UMR-7225; Assistance Publique-Hôpitaux de Paris (AP-HP); and Institut du Cerveau et de la Moe
  • Muldmaa M; Movement Disorders Unit Department of Neurology Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) Madrid Spain.
  • Mueller C; Department of Neurology Complejo Asistencial de Segovia Segovia Spain.
  • Pinter B; Second Department of Neurology Faculty of Medicine Comenius University Bratislava Slovak Republic.
  • Poewe W; Department of Neurology University of Miami Miami Florida USA.
  • Rallmann K; Department of Neurology North Estonian Medical Center Tallinn Estonia.
  • Reiter E; Department of Neurology Medical University of Innsbruck Innsbruck Austria.
  • Rodriguez-Blazquez C; Department of Neurology Medical University of Innsbruck Innsbruck Austria.
  • Singer C; Department of Neurology Medical University of Innsbruck Innsbruck Austria.
  • Tilley BC; Department of Neurology and Neurosurgery University of Tartu Tartu Estonia.
  • Valkovic P; Department of Neurology Medical University of Innsbruck Innsbruck Austria.
  • Goetz CG; National Center of Epidemiology and Centro de Investigación Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED) Carlos III Institute of Health Madrid Spain.
  • Stebbins GT; Department of Neurology University of Miami Miami Florida USA.
Mov Disord Clin Pract ; 4(4): 536-544, 2017.
Article em En | MEDLINE | ID: mdl-30363418
ABSTRACT

BACKGROUND:

The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a newly developed tool to assess Parkinson's disease (PD). Changes in scores on the scale over the course of PD, including increasing disease duration and Hoehn and Yahr (HY) stages, have not been described. The objectives of this study were to analyze MDS-UPDRS scores on Parts I through IV and their differences based on HY stage and disease duration in a large cohort of patients with PD.

METHODS:

For this cross-sectional study, demographic data and MDS-UPDRS scores were collected, including HY stage. Subscores on MDS-UPDRS Parts I through IV were analyzed using 1-way analyses of variance for each HY stage and in 5-year increments of disease duration. Part III (motor assessment) scores were analyzed separately for on and off states.

RESULTS:

The mean age of the 3206 patients was 65.8 ± 10.6 years, 53.3% were men, the mean disease duration was 11.5 ± 4.6 years, and the median HY stage was 2 (range, 0-5); 2156 patients were examined in an on state and 987 were examined in an off state. Scores for all MDS-UPDRS parts increased significantly through HY stages 1 through 5, with an average increase of 3.8, 7.7, 14.6, and 2.0 points consecutively for parts I through IV, respectively. For the 5-year increments of disease duration, MDS-UPDRS subscores increased by an average of 1.6, 3.3, 4.2, and 1.4 points consecutively for parts I through IV, respectively. This increase was significant only during the first 15 years of disease for all 4 parts, including part III scores evaluated in both on and off states.

CONCLUSIONS:

MDS-UPDRS scores for all 4 parts increase significantly with every HY stage and also with 5-year increments of disease duration in the first 15 years of the disease.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Mov Disord Clin Pract Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Mov Disord Clin Pract Ano de publicação: 2017 Tipo de documento: Article